Theragenics Corp (NYSE:TGX)

CAPS Rating: 5 out of 5

A medical device company serving the cancer treatment and surgical markets. The Company produces, markets and sells TheraSeed(r), its premier palladium-103 prostate cancer treatment device and I-Seed, its iodine-125 based prostate cancer treatment device.


Player Avatar NeroSagetrade (89.46) Submitted: 12/12/2007 12:34:19 AM : Outperform Start Price: $4.00 TGX Score: -88.66

Theragenics is one of the select few healthcare companies that really does provide a nice value. TGX is trading below book value and at just 15-20 times forward earnings estimates. Revenue growth has been steadily showing 10-12M increases for 4 years now and they are set with more than 45 million in cash and only 7 million in debt. The long-term downtrend has been broken as of earlier this year so it should be able to mount a run at its yearly highs of 2007 in 2008/2009. There's no reason these fundamentals should go unnoticed.


Featured Broker Partners